Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 7/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.51 |
| ▸ | METAP2 | P50579 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.48 |
| ▸ | USP2 | O75604 | 2/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26739769 | 0.79 | CYP1A2 (0.50) | CYP1A2CYP3A4ALDH1A1HSD17B10TDP1 | |
| SCHEMBL9764797 | 0.79 | CCR1 (0.52) | CYP1A2CYP3A4ALDH1A1HSD17B10TDP1 | |
| SCHEMBL24497548 | 0.79 | METAP2 (0.51) | CYP1A2CYP3A4ALDH1A1HSD17B10TDP1 | |
| SCHEMBL29739505 | 0.78 | HSP90AA1 (0.50) | ALDH1A1HSD17B10CYP11B1CYP11B2METAP2 | |
| SCHEMBL16321239 | 0.78 | METAP2 (0.50) | CYP1A2CYP3A4ALDH1A1HSD17B10TDP1 | |
| SCHEMBL16364563 | 0.78 | METAP2 (0.50) | CYP1A2CYP3A4ALDH1A1HSD17B10TDP1 | |
| SCHEMBL14988502 | 0.78 | HSP90AA1 (0.50) | ALDH1A1HSD17B10CYP11B1CYP11B2METAP2 | |
| SCHEMBL26739772 | 0.78 | DHODH (0.51) | ALDH1A1CYP11B1CYP11B2MAPTSMN1; SMN2 | |
| SCHEMBL13561342 | 0.75 | METAP2 (0.47) | CYP1A2CYP3A4ALDH1A1HSD17B10TDP1 | |
| SCHEMBL25109898 | 0.75 | METAP2 (0.47) | CYP1A2CYP3A4ALDH1A1HSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-11912682-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912682-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230348418-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2023-11-02 | — | — | US | disclosed |
| US-20230348418-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2023-11-02 | — | — | US | disclosed |
| WO-2012043891-A1 | AGENT FOR TREATMENT OF EYE DISEASES | ダイトーケミックス株式会社 (JP) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012014994-A1 | NAPHTHALENE DERIVATIVE | ダイトーケミックス株式会社 (JP) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | UPF1, NSUN2, RTF2 | CYP1A2 1677/4885CYP3A4 3128/4885ALDH1A1 4150/4885 |
| US-20230348418-A1 | ISOINDOLINONE COMPOUNDS | CYP4F2, AOC2, AOC3 | CYP1A2 170/4885CYP3A4 715/4885ALDH1A1 1370/4885 |
| US-11912682-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | CYP1A2 146/4885CYP3A4 684/4885ALDH1A1 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.